Kinetics of antibody responses dictate COVID-19 outcome
Summary Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levelsper se, but rather with the delayed kinetics of NAb production..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 08. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lucas, Carolina [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.12.18.20248331 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019586825 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019586825 | ||
| 003 | DE-627 | ||
| 005 | 20230429085720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201229s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.18.20248331 |2 doi | |
| 035 | |a (DE-627)XBI019586825 | ||
| 035 | |a (biorXiv)10.1101/2020.12.18.20248331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lucas, Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kinetics of antibody responses dictate COVID-19 outcome |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levelsper se, but rather with the delayed kinetics of NAb production. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Klein, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Sundaram, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Feimei |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Tianyang |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Ji Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuyama, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Peiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Venkataraman, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Annsea |e verfasserin |4 aut | |
| 700 | 1 | |a Israelow, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Wyllie, Anne L. |e verfasserin |4 aut | |
| 700 | 1 | |a Vogels, Chantal B. F. |e verfasserin |4 aut | |
| 700 | 1 | |a Muenker, M. Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Casanovas-Massana, Arnau |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Wade L. |e verfasserin |4 aut | |
| 700 | 1 | |a Zell, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, John B. |e verfasserin |4 aut | |
| 700 | 1 | |a Grubaugh, Nathan D. |e verfasserin |4 aut | |
| 700 | 1 | |a Farhadian, Shelli |e verfasserin |4 aut | |
| 700 | 1 | |a Wisnewski, Adam V. |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Charles Dela |e verfasserin |4 aut | |
| 700 | 1 | |a Omer, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Albert I. |e verfasserin |4 aut | |
| 700 | 1 | |a Ring, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Akiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 08. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.18.20248331 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 12 | ||